Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials

BACKGROUND: Irritable bowel syndrome with diarrhea (IBS-D) is a prevalent gastrointestinal (GI) disorder with a varied presentation, often overlapping with other GI and non-GI disorders. Eluxadoline is a locally active mixed µ- and κ-opioid receptor agonist and δ-opioid receptor antagonist approved...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacy, Brian E., Harris, Lucinda A., Chang, Lin, Lucak, Susan, Gutman, Catherine, Dove, Leonard S., Covington, Paul S., Lembo, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466471/
https://www.ncbi.nlm.nih.gov/pubmed/31019552
http://dx.doi.org/10.1177/1756284819841290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466471/
https://www.ncbi.nlm.nih.gov/pubmed/31019552
http://dx.doi.org/10.1177/1756284819841290

Ejemplares similares